US 8815229
Granulysin in immunotherapy
granted A61KA61K2039/55516A61K2039/55522
Quick answer
US patent 8815229 (Granulysin in immunotherapy) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K2039/55516, A61K2039/55522, A61K2039/55527, A61K2239/57